{
    "title": "115_s348",
    "content": "The Act titled \"Prescription Drug and Health Improvement Act of 2017\" allows for negotiating fair prices for Medicare prescription drugs. The Prescription Drug and Health Improvement Act of 2017 allows for negotiating fair prices with drug manufacturers for Medicare prescription drugs. The Secretary is authorized to negotiate prices for covered part D drugs to provide quality care and contain costs. The Prescription Drug and Health Improvement Act of 2017 authorizes the Secretary to negotiate prices for Medicare prescription drugs, considering various factors like current price, launch price, usage, and effectiveness compared to alternatives. If negotiations fail, the lower of VA or big four price is used. The Secretary can establish the price for a covered part D drug if negotiations fail after 1 year. The price charged to PDP sponsors and MA organizations will be the lesser of the price paid by the Secretary of Veterans Affairs or the price paid under section 8126 of title 38, United States Code. The term 'applicable covered part D drug' is defined based on factors like spending, unit price increases, availability of alternative treatments, and other criteria determined by the Secretary. PDP sponsors and MA organizations may negotiate lower prices. The Secretary allows PDP sponsors and MA organizations to negotiate lower prices for covered part D drugs, without affecting the existing appeals process. The amendments made by this subsection will be effective starting January 1, 2019. The Secretary of Health and Human Services must report to Congress every 6 months on negotiations for lower drug prices for Medicare beneficiaries starting January 1, 2019. The Secretary of Health and Human Services must report to Congress every 6 months on spending data for covered part D drugs for Medicare beneficiaries, including drugs with high costs and unit cost increases over the past five years. The Secretary of Health and Human Services must report to Congress every 6 months on spending data for covered part D drugs for Medicare beneficiaries, including drugs with no therapeutic substitute, access to these drugs, and appeals by enrollees regarding drugs not on plan formularies. The reports will be publicly available on the Centers for Medicare & Medicaid Services website. Additionally, a study on negotiations will be conducted by the Comptroller General of the United States. States will conduct a study on negotiations by the Secretary under the Social Security Act to achieve lower prices for covered part D drugs for Medicare beneficiaries. The Comptroller General will submit a report to Congress by January 1, 2022, with recommendations for improving negotiations. Additionally, there will be CMI testing of negotiating drug and biological prices to improve value under the Social Security Act. The Social Security Act will be amended to include at least 3 models for negotiating drug and biological prices to improve value within 18 months of the enactment of the Prescription Drug and Health Improvement Act of 2017. These models aim to enhance the value of payments for drugs under applicable titles, including parts B and D of title XVIII. The Prescription Drug and Health Improvement Act of 2017 will introduce various strategies to enhance the value of payments for drugs and biologicals, including discounting patient cost-sharing, value-based formularies, indications-based pricing, reference pricing, risk-sharing agreements, pricing based on comparative effectiveness research, and episode-based payments for certain conditions."
}